Clinical trials: Glabellar Lines
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770211
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States
- Volunteers
- 271 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT_BTA_P3_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after…
- Trial name
- NCT06124794
- Testing
- PROTOXIN
- Where
- 3 sites in South Korea
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Lines, Wrinkles
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines. 1.
- Trial name
- NCT02718118
- Testing
- Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA I (NCT04594213)
- Testing
- NT 201
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
- Trial name
- NCT04830345
- Testing
- ATGC-100 100U, Botox 100U
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Glabellar Frown Lines
A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines
A randomized, evaluator-blinded, comparative, study to evaluate the efficacy and safety of different injection volumes of botulinum toxin type A, Azzalure, in the glabellar lines.
- Trial name
- NCT02108158
- Testing
- Azzalure
- Where
- 2 sites in Sweden
- Volunteers
- 62 people
- Sponsor
- Galderma R&D
Lateral Canthal Lines, Crow's Feet Lines
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.
- Trial name
- NCT02248844
- Testing
- Botulinum Toxin Type A
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Allergan
Glabellar Frown Lines
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
- Trial name
- NCT05146999
- Testing
- QM1114-DP
- Where
- 9 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan
Glabellar Frown Lines
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
- Trial name
- NCT06411002
- Testing
- DAXXIFY
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revance Therapeutics, Inc.
Crow's Feet Lines, Glabellar Lines
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.
- Trial name
- NCT03184363
- Testing
- Clostridium Botulinum A Toxin
- Volunteers
- 102 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Skin Aging
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
The purpose of this study is to test the hypothesis that the efficacy and safety of Meditoxin® are not inferior to Botox®'s in the treatment of glabellar lines.
- Trial name
- NCT01237977
- Testing
- Botulinum Toxin Type A(Meditoxin®), Botulinum Toxin Type A(Botox®)
- Where
- 6 sites in South Korea
- Volunteers
- 314 people
- Sponsor
- Medy-Tox
Moderate to Severe Glabellar Lines
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 3, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate the efficacy and safety of 50 units (U) of QM1114-DP for the treatment of moderate to severe GL in male and…
- Trial name
- NCT05463965
- Testing
- QM1114-DP, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Lines
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.
- Trial name
- NCT05428930
- Testing
- CKDB-501B, Botox®50U
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- CKD Bio Corporation
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
- Trial name
- NCT03721016
- Testing
- MT10109L
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 415 people
- Sponsor
- Medy-Tox
Moderate to Severe Glabellar Lines
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male…
- Trial name
- NCT05743634
- Testing
- YY001, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 140 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Recombinant Collagen Freeze-Dried Fibre for Upper Facial Wrinkles
The goal of this clinical trial was to learn whether a collagen filler improved facial wrinkles. The study product was injectable recombinant collagen freeze-dried fibers.
- Trial name
- NCT07897773
- Testing
- Recombinant Collagen Freeze-Dried Fibers, Collagen Implant
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Shaanxi Giant Biotechnology Co., Ltd
Glabellar Lines
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin.
- Trial name
- NCT05248893
- Testing
- AGN-151586
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 992 people
- Sponsor
- AbbVie
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS I (NCT02677298)
- Testing
- Botulinum Toxin A
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Croma-Pharma GmbH